

According to the UN GHS revision 8

Creation Date: May 27, 2024

Revision Date: May 27, 2024

1. IDENTIFICATION

1.1 GHS Product identifier

Product name: Doxorubicin

Catalog Number: T1456

CAS Number: 23214-92-8

1.2 Other means of identification

Other names: -

1.3 Recommended use of the chemical and restrictions on use

Identified uses: no data available

1.4 Supplier's details

Company: Targetmol Chemicals Inc.

Uses advised against: 36 Washington Street, Wellesley Hills, Massachusetts 02481 USA

Tel/Fax: (781) 999-4286

1.5 Emergency phone number

Emergency phone number: 781-999-4286

Service hours: Monday to Friday, 9am-5pm (Standard timezone: UTC/GMT -5hours).

2. HAZARD IDENTIFICATION

2.1 Classification of the substance or mixture

Acute toxicity - Category 4, Oral

Carcinogenicity, Category 1B

2.2 GHS label elements, including precautionary statements

Pictogram(s):



Signal word: Danger

Hazard statement(s):
H302 Harmful if swallowed
H350 May cause cancer

Precautionary statement(s):

Prevention:
P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...

Response:
P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
P318 IF exposed or concerned, get medical advice.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance

with applicable laws and regulations, and product characteristics at time of disposal.

2.3 Other hazards which do not result in classification

no data available

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Chemical name	Common names and synonyms	CAS number	EC number
Doxorubicin	-	23214-92-8	245-495-6

4. FIRST-AID MEASURES

4.1 Description of necessary first-aid measures

General advice

no data available

If inhaled

Move the victim into fresh air. If breathing is difficult, give oxygen. If not breathing, give artificial respiration and consult a doctor immediately. Do not use mouth to mouth resuscitation if the victim ingested or inhaled the chemical.

Following skin contact

Take off contaminated clothing immediately. Wash off with soap and plenty of water. Consult a doctor.

Following eye contact

Rinse with pure water for at least 15 minutes. Consult a doctor.

Following ingestion

Rinse mouth with water. Do not induce vomiting. Never give anything by mouth to an unconscious person. Call a doctor or Poison Control Center immediately.

4.2 Most important symptoms/effects, acute and delayed

Treatment of acute overdosage consists of treatment of the severely myelosuppressed patient with hospitalization, antimicrobials, platelet transfusions and symptomatic treatment of mucositis. Use of hemopoietic growth factor (G-CSF, GM-CSF) may be considered. The 150 mg doxorubicin hydrochloride for injection and the 75 mL and 100 mL (2 mg/mL) doxorubicin hydrochloride injection vials are packaged as multiple dose vials and caution should be exercised to prevent inadvertent overdosage. Cumulative dosage with doxorubicin increases the risk of cardiomyopathy and resultant congestive heart failure. Treatment consists of vigorous management of congestive heart failure with digitalis preparations, diuretics, and after-load reducers such as ACE inhibitors.

4.3 Indication of immediate medical attention and special treatment needed, if necessary

no data available

5. FIRE-FIGHTING MEASURES

5.1 Extinguishing media

Use dry chemical, carbon dioxide or alcohol-resistant foam.

5.2 Specific hazards arising from the chemical

no data available

5.3 Special protective actions for fire-fighters

Wear self-contained breathing apparatus for firefighting if necessary.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Avoid dust formation. Avoid breathing mist, gas or vapours. Avoid contacting with skin and eye. Use personal protective equipment. Wear chemical impermeable gloves. Ensure adequate ventilation. Remove all sources of ignition. Evacuate personnel to safe areas. Keep people away from and upwind of spill/leak.

6.2 Environmental precautions

Prevent further spillage or leakage if it is safe to do so. Do not let the chemical enter drains. Discharge into the environment must be avoided.

6.3 Methods and materials for containment and cleaning up

PRECAUTIONS FOR "CARCINOGENS": A high-efficiency particulate arrestor (HEPA) or charcoal filters can be used to minimize amt of carcinogen in exhausted air ventilated safety cabinets, lab hoods, glove boxes or animal rooms ... Filter housing that is designed so that used filters can be transferred into plastic bag without contaminating maintenance staff is avail commercially. Filters should be placed in plastic bags immediately after removal ... The plastic bag should be sealed immediately ... The sealed bag should be labelled properly ... Waste liquids ... should be placed or collected in proper containers for disposal. The lid should be secured & the bottles properly labelled. Once filled, bottles should be placed in plastic bag, so that outer surface ... is not contaminated ... The plastic bag should also be sealed & labelled. ... Broken glassware ... should be decontaminated by solvent extraction, by chemical destruction, or in specially designed incinerators. Chemical Carcinogens

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

7.2 Conditions for safe storage, including any incompatibilities

Commercially available doxorubicin hydr^oChloride lyophilized powder for injection should be stored in a dry place protected from sunlight. When stored at 15-30 deg C, Adriamycin RDF or Rubex has an expiration date of 3 or 2 years, respectively, following the date of manufacture. Doxorubicin hydr^oChloride conventional (nonencapsulated) injection should be protected from light and refrigerated at 2-8 deg C; when stored under these conditions, the injection is stable for 18 months

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Occupational Exposure limit values

no data available

Biological limit values

no data available

8.2 Appropriate engineering controls

Ensure adequate ventilation. Handle in accordance with good industrial hygiene and safety practice. Set up emergency exits and the risk-elimination area.

8.3 Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection

Wear tightly fitting safety goggles with side-shields conforming to EN 166(EU) or NIOSH (US).

Skin protection

Wear fire/flammable resistant and impervious clothing. Handle with gloves. Gloves must be inspected prior to use. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.

Respiratory protection

If the exposure limits are exceeded, irritation or other symptoms are experienced, use a full-face respirator.

Thermal hazards

no data available

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	Solid
Color	Red, crystalline solid
Odour	no data available
Melting point/ freezing point	205°C

Boilingpoint or initial boiling point and boiling range	no data available
Flammability	no data available
Lower and upper explosion limit/flammability limit	no data available
Flash point	443.8°C
Auto-ignition temperature	no data available
Decomposition temperature	no data available
pH	no data available
Kinematic viscosity	no data available
Solubility	H2O: 50mg/mL DMSO: 10 mM,
N-octanol-water partition coefficient	no data available
Vapour pressure	9.64E-28mmHg at 25°C
Density and/ or relative density	1.61 g/cm3
Relative vapour density	no data available
Particle characteristics	no data available

10. STABILITY AND REACTIVITY

10.1 Reactivity

no data available

10.2 Chemical stability

Neutral aq soln are stable at room temp

10.3 Possibility of hazardous reactions

no data available

10.4 Conditions to avoid

no data available

10.5 Incompatible materials

Doxorubicin hydr^oChloride solution is chemically incompatible with heparin sodium injection, and a precipitate may form if the solutions are mixed. Doxorubicin hydr^oChloride solution also is reportedly incompatible with fluorouracil, and a precipitate may form if the solutions are mixed. The manufacturers recommend that doxorubicin hydr^oChloride solutions or doxorubicin liposomal dispersion generally not be mixed with other drugs; specialized references should be consulted for specific compatibility information.

10.6 Hazardous decomposition products

When heated to decomposition /temp unspecified/, adriamycin emits toxic fumes of ... /nitrogen oxides/ and hydr^oChloric acid.

11. TOXICOLOGICAL INFORMATION

Acute toxicity

Oral: LD50 Mouse oral 570 mg/kg
Inhalation: no data available
Dermal: no data available

Skin corrosion/irritation

no data available

Serious eye damage/irritation

no data available

Respiratory or skin sensitization

no data available

Germ cell mutagenicity

no data available

Carcinogenicity

Inadequate evidence of carcinogenicity in humans. Sufficient evidence of carcinogenicity in animals. OVERALL EVALUATION: Group 2A: The agent is probably carcinogenic to humans.

Reproductive toxicity

no data available

STOT-single exposure

no data available

STOT-repeated exposure

no data available

Aspiration hazard

no data available

12. ECOLOGICAL INFORMATION

12.1 Toxicity

Toxicity to fish: no data available

Toxicity to daphnia and other aquatic invertebrates: EC50; Species: Daphnia magna (Water flea); Concentration: 2.0 mg/L; Effect: immobilization / Conditions of bioassay not specified in source examined

Toxicity to algae: no data available

Toxicity to microorganisms: no data available

12.2 Persistence and degradability

no data available

12.3 Bioaccumulative potential

An estimated BCF of 0.5 was calculated in fish for doxorubicin(SRC), using a log Kow of 1.27(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

12.4 Mobility in soil

Using a structure estimation method based on molecular connectivity indices(1), the K_{oc} of doxorubicin can be estimated to be 6,000 (SRC). According to a classification scheme(2), this estimated K_{oc} value suggests that doxorubicin is expected to be immobile in soil. Estimated values for pKa1, pKa2, and pKa3 of 7.34, 8.46, and 9.46, respectively(3), indicate that this compound will exist almost entirely in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4).

12.5 Other adverse effects

no data available

13. DISPOSAL CONSIDERATIONS

13.1 Disposal methods

Product

The material can be disposed of by removal to a licensed chemical destruction plant or by controlled incineration with flue gas scrubbing. Do not contaminate water, foodstuffs, feed or seed by storage or disposal. Do not discharge to sewer systems.

Contaminated packaging

Containers can be triply rinsed (or equivalent) and offered for recycling or reconditioning. Alternatively, the packaging can be punctured to make it unusable for other purposes and then be disposed of in a sanitary landfill. Controlled incineration with flue gas scrubbing is possible for combustible packaging materials.

A DRUG SCREENING EXPERT

14. TRANSPORT INFORMATION

14.1 UN Number

no data available

14.2 UN Proper Shipping Name

no data available

14.3 Transport hazard class(es)

no data available

14.4 Packing group, if applicable

no data available

14.5 Environmental hazards

no data available

14.6 Special precautions for user

no data available

14.7 Transport in bulk according to IMO instruments

no data available

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations specific for the product in question

European Inventory of Existing Commercial Chemical Substances (EINECS)	Listed.
EC Inventory	Listed.
United States Toxic Substances Control Act (TSCA) Inventory	Not Listed.
China Catalog of Hazardous chemicals 2015	Not Listed.
New Zealand Inventory of Chemicals (NZI ^o C)	Listed.
Philippines Inventory of Chemicals and Chemical Substances (PICCS)	Not Listed.
Vietnam National Chemical Inventory	Not Listed.
Chinese Chemical Inventory of Existing Chemical Substances (China IECSC)	Not Listed.
Korea Existing Chemicals List (KECL)	Not Listed.

16. OTHER INFORMATION

Information on revision

Creation Date May 27, 2024

Revision Date May 27, 2024

Abbreviations and acronyms

- CAS: Chemical Abstracts Service
- ADR: European Agreement concerning the International Carriage of Dangerous Goods by Road
- RID: Regulation concerning the International Carriage of Dangerous Goods by Rail
- IMDG: International Maritime Dangerous Goods
- IATA: International Air Transportation Association
- TWA: Time Weighted Average
- STEL: Short term exposure limit
- LC50: Lethal Concentration 50%
- LD50: Lethal Dose 50%
- EC50: Effective Concentration 50%

References

IPCS - The International Chemical Safety Cards (ICSC), website: <http://www.ilo.org/dyn/icsc/showcard.home>
HSDB - Hazardous Substances Data Bank, website: <https://toxnet.nlm.nih.gov/newtoxnet/hsdb.htm>
IARC - International Agency for Research on Cancer, website: <http://www.iarc.fr/>
eChemPortal - The Global Portal to Information on Chemical Substances by OECD, website: http://www.echemportal.org/echemportal/index?pageID=0&request_l°Cale=en
CAMEO Chemicals, website: <http://cameochemicals.noaa.gov/search/simple>
ChemIDplus, website: <http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp>
ERG - Emergency Response Guidebook by U.S. Department of Transportation, website: <http://www.phmsa.dot.gov/hazmat/library/erg>
Germany GESTIS-database on hazard substance, website: <http://www.dguv.de/ifa/gestis/gestis-stoffdatenbank/index-2.jsp>
ECHA - European Chemicals Agency, website: <https://echa.europa.eu/>

Other Information

no data available

Disclaimer: The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. We as supplier shall not be held liable for any damage resulting from handling or from contact with the above product.
All products are for Research Use Only · Not For Human or Veterinary or Therapeutic Use